Aminopyridines: selective AuroraA inhibitors: Banyu Pharmaceutical Co. Ltd: WO2006046735
Aurora inhibitors have been extensively studied as potential novel anticancer agents. At least four compounds are now under clinical evaluation. Banyu discloses aminopyridines and -pyrazines acting as selective Aurora-A inhibitors. The claimed compounds demonstrated low nanomolar activity in the bio...
Gespeichert in:
| Veröffentlicht in: | Expert opinion on therapeutic patents 2007-02, Vol.17 (2), p.255-261 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | Aurora inhibitors have been extensively studied as potential novel anticancer agents. At least four compounds are now under clinical evaluation. Banyu discloses aminopyridines and -pyrazines acting as selective Aurora-A inhibitors. The claimed compounds demonstrated low nanomolar activity in the biochemical assay and exhibit a 200-fold specificity on Aurora-A versus Aurora-B. |
|---|---|
| ISSN: | 1354-3776 1744-7674 |
| DOI: | 10.1517/13543776.17.2.255 |